Use of sildenafil for female sexual dysfunction

Annals of Pharmacotherapy

Volumn 40, Issue 5, 2006, Pages 931-934

  Shields, Kelly M ^a   Hrometz, Sandra L ^a  

^a OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

Female sexual dysfunction; Phosphodiesterase inhibitors; Sildenafil

Indexed keywords

CYCLIC AMP; CYCLIC GMP; HORMONE; NEUROTRANSMITTER; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANXIETY; CLINICAL TRIAL; CLITORIS; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FEMALE SEXUAL DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; LUBRICATION; NOSE CONGESTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RHINITIS; SEXUAL AROUSAL; SEXUAL SATISFACTION; VISUAL DISORDER;

FEMALE; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 33646760231     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G471     Document Type: Review

References (26)

1. Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000;163:888-93.
2. Meston CM, Frohlich PF. Update on female sexual function. Curr Opin Urol 2001;11:603-9.
3. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44.
4. Simons JS, Carey MP. Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav 2001;30:177-219.
5. Kaplan HS. Disorders of sexual desire and other new concepts and techniques in sex therapy. 1st ed. New York: Brunner/Hazel Publications, 1979.
6. Basson R. Human sex response cycles. J Sex Marital Ther 2001;27:33-43.
7. Basson R. The female sexual response: a different model. J Sex Marital Ther 2000;26:51-65.
8. Cellek S, Moncada S. Nitrergic neurotransmission mediates the non-adrenergic non-cholinergic responses in the clitoral corpus cavernosum of the rabbit. Br J Pharmacol 1998;125:1627-9.
9. Hoyle CH, Stones RW, Robson T, Whitley K, Burnstock G. Innervation of vasculature and microvasculature of the human vagina by NOS and neuropeptide-containing nerves. J Anat 1996;188(pt 3):633-44.
10. Ziessen T, Moncada S, Cellek S. Characterization of the non-nitrergic NANC relaxation responses in the rabbit vaginal wall. Br J Pharmacol 2002;135:546-54.
11. Helm G, Ottesen B, Fahrenkrug J, et al. Vasoactive intestinal polypeptide (VIP) in the human female reproductive tract: distribution and motor effects. Biol Repro 1981;25:227-34.
12. Burnett AL, Calvin DC, Silver RI, Peppas DS, Docimo SG. Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. J Urol 1997;158:75-8.
13. Ottesen B, Ulrichsen H, Fahrenkrug J, Larsen JJ, Wagner G, Schierup L. Vasoactive intestinal polypeptide and the female genital tract: relationship to reproductive phase and delivery. Am J Obstet Gynecol 1982;143:414-20.
14. Ottesen B, Gerstenberg T, Ulrichsen H, Manthorpe T, Fahrenkrug J, Wagner G. Vasoactive intestinal polypeptide (VIP) increases vaginal blood flow and inhibits uterine smooth muscle activity in women. Eur J Clin Invest 1983;13:321-4.
15. Ottesen B, Pedersen B, Nielsen J, Dalgaard D, Wagner G, Fahrenkrug J. Vasoactive intestinal polypeptide (VIP) provokes vaginal lubrication in normal women. Peptides 1987;8:797-800.
16. Palle C, Bredkjaer HE, Ottesen B, Fahrenkrug J. Vasoactive intestinal polypeptide and human vaginal blood flow: comparison between transvaginal and intravenous administration. Clin Exp Pharmacol Physiol 1990;17:61-8.
17. Levin RJ. VIP, vagina, clitoral and periurethral glans-an update on human female genital arousal. Exp Clin Endocrinol 1991;98:61-9.
18. Berman J, Adhikari SP, Goldstein I. Anatomy and physiology of female sexual function and dysfunction: classification, evaluation and treatment options. Eur Urology 2000;38:20-9.
19. Burnett AL, Calvin DC, Silver RI, Peppas DS, Docimo SG. Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. J Urol 1997;158:75-8.
20. Park K, Moreland RB, Goldstein I, Atala A, Traish A. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1998;249:612-7.
21. Fourcroy JL. Female sexual dysfunction: potential for pharmacotherapy. Drugs 2003;63:1445-57.
22. Berman JR, Berman LA, Toler SM, Gill J, Haugie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study. J Urol 2003;170:2333-8.
23. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001;108:623-8.
24. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Wom Health Gender-Based Med 2002;11:367-77.
25. Kaplan SA, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999;53:481-6.
26. Berman JR, Berman LA, Lin H, Flaherty E, Lahey N, Goldstein I. Effect of sildenafil on subjective and physiologic parameters in women with sexual arousal disorder. J Sex Marital Ther 2001;27:411-20.